This synergy operates through multiple mechanisms: Complementary signaling : Sermorelin activates cAMP/PKA while ipamorelin activates PLC/PKC, and both pathways converge on calcium mobilization for GH exocytosis Somatostatin suppression : Ipamorelin (via GHS-R1a) suppresses hypothalamic somatostatin release, while sermorelin's effects are regulated by somatostatin -- reducing this brake enhances sermorelin's action GH synthesis plus release : Sermorelin increases GH gene transcription and pituitary reserve, while ipamorelin triggers release of the accumulated GH stores The combined GHRH + GHRP approach is a well-documented strategy in growth hormone secretagogue research, and the ipamorelin-sermorelin combination specifically has gained attention due to ipamorelin's clean hormonal profile (no cortisol or prolactin stimulation) paired with sermorelin's established clinical track record
The STEP and SUSTAIN trial data provide robust evidence of systemic anti-inflammatory effects
ALLERGENS: Contains no preservatives, corn, dairy, gluten, soy, wheat or yeast.
The FDA has expanded the indication for both tirzepatide and semaglutide, in combination with a reduced calorie diet and increased physical activity, to reduce the risk of cardiovascular death, heart attack and stroke in adults with cardiovascular disease who are overweight or obese
Compounded medication advisory: Tirzepatide, Semaglutide, Bella & Lipo Burn are all compounded medications